Du, Yunpeng, V. P. Sarthy, T. S. Kern. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol 287: R735-R741, 2004; 10.1152/ajpregu.00080.2003.-A nonselective inhibitor of cyclooxygenase (COX; high-dose aspirin) and a relatively selective inhibitor of inducible nitric oxide synthase (iNOS; aminoguanidine) have been found to inhibit development of diabetic retinopathy in animals, raising a possibility that NOS and COX play important roles in the development of retinopathy. In this study, the effects of hyperglycemia on retinal nitric oxide (NO) production and the COX-2 pathway, and the interrelationship of the NOS and COX-2 pathways in retina and retinal cells, were investigated using a general inhibitor of
PROSTAGLANDINS AND NITRIC OXIDE (NO) are important mediators of inflammation, cell growth, and homeostasis. A possible role of these molecules in the pathogenesis of diabetic retinopathy has been suggested by findings that the development of diabetic retinopathy in animals was inhibited by a nonselective inhibitor of cyclooxygenase (COX; high-dose aspirin) and by a relatively selective inhibitor of inducible NO synthase (iNOS; aminoguanidine) (13, 14, 18, 20) .
Both COX and NOS have constitutive and inducible isoforms. The inducible isoforms (COX-2 and iNOS) have been reported to contribute to cytotoxicity in some cell types via production of proinflammatory prostaglandins, NO, superoxide, and peroxynitrite (1, 15, 44) . Moreover, there is evidence that these two enzymes can regulate the activity of each other (31, 35) . Whether this occurs in retina in diabetes is not clear.
In this study, we use diabetic rats in vivo, as well as transformed retinal Müller (glial) cells (rMC-1) and bovine retinal endothelial cells (BREC) in culture, to investigate 1) the diabetes-induced alterations of the NO and prostaglandin pathways in the retina, 2) the interrelation of NOS and COX pathways, and 3) the contribution of these pathways to death of retinal cells induced by elevated glucose concentration. In addition, we investigated the effect of therapies previously reported to inhibit retinopathy in diabetic animals (aminoguanidine and aspirin) on iNOS and COX-2.
MATERIALS AND METHODS
Aminoguanidine, aspirin, L-N 6 -(1-iminoethyl)lysine (L-NIL), N Gnitro-L-arginine methyl ester (L-NAME), HEPES, penicillin-streptomycin solution, and trypsin-EDTA solution were purchased from Sigma Chemicals (St. Louis, MO). COX-2 inhibitors NS-398 and meloxicam (ME) were purchased from Calbiochem (San Diego, CA).
Müller Cell Culture
Transformed retinal Müller (glial) cells (rMC-1 cell line) (39) were cultured and passaged in DMEM medium containing 5 mM glucose and 10% FBS. When cells were 50% confluent, the proliferation rate was slowed down by reducing the concentration of fetal calf serum in 5 or 25 mM glucose media to 2%, and the experiments were immediately conducted. Cells were incubated in 5 or 25 mM glucose, with or without aminoguanidine (10 g/ml, 90 M), aspirin (2 mM), L-NIL (30 M), L-NAME (1 mM), NS-398 (50 M), or meloxicam (50 M). L-NIL is a selective iNOS inhibitor, having an IC50 value for iNOS of 3.3 M compared with IC50 values for neuronal NOS (nNOS) of 92 M and endothelial NOS (eNOS) of 138 M, respectively (12, 30) . L-NAME is a nonselective inhibitor of nitric oxide synthetases; it exhibits K i values of 15 nM, 39 nM, and 4.4 M for nNOS (bovine), eNOS (human), and iNOS (murine), respectively (9, 11) . NS-398 and meloxicam are selective COX-2 inhibitors, having IC50 values for COX-2 of 0.32 and 4.7 M, respectively, compared with IC50 values for COX-1 of Ͼ100 and 36.6 M, respectively (4, 33) . Media were changed every other day for up to 5 days. Cells were harvested by treating with a trypsin-EDTA solution [0.5% and 0.02%, respectively (wt/vol)].
Endothelial Cell Culture
Primary bovine retinal endothelial cells (BREC; between 5th and 10th passages) were grown on fibronectin-coated dishes (Iwaki Glass, Tokyo) containing EBM (Clonetics, Santa Rosa, CA) with 5 mM glucose, 10% plasma-derived horse serum, 50 mg/l heparin, and 50 mg/l endothelial cell growth factor (Boehringer Mannheim, Indianapolis, IN). The cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 and grown until 50% confluent. Cells were incubated in 5 or 25 mM glucose as well as inhibitors as described above, and media were changed every other day for up to 5 days. Cells were harvested by treating with a trypsin-EDTA solution [0.5 and 0.02%, respectively (wt/vol)]. The cells were identified as endothelial cells on the basis of their cobblestone morphology and by the presence of von Willebrand factor, shown by immunofluorescence staining.
Animals
Male Sprague-Dawley rats (225-250 g) were randomly assigned to become diabetic or remain as nondiabetic group for 2 mo. Diabetes was induced by intraperitoneal injection of freshly prepared solution of streptozotocin in citrate buffer (pH 4.5) at 55 mg/kg body wt. Diabetic rats randomly were assigned to receive aminoguanidine (3.0 g/kg diet) or aspirin (0.19 g/kg diet) with their diet or to remain as untreated diabetic control. These concentrations yielded daily intakes similar to those found previously by us to inhibit the development of lesions of early retinopathy in diabetic rats and to inhibit the apoptotic death of retinal capillary cells in diabetes (Ref. 20 and unpublished observations). Insulin was given as needed to achieve slow weight gain without preventing hyperglycemia and glucosuria (0 -2 U of neutral protamine hagedorn insulin sc, 0 -3 times/wk). Thus diabetic rats were insulin deficient but not grossly catabolic. All animals had free access to food and water and were maintained under a 14 h on/10 h off light cycle. Glycated hemoglobin (an estimate of the average level of hyperglycemia over the previous 2 mo) was measured by affinity chromatography (Glyc-Affin; Pierce, Rockford, IL) just before animals were killed. Food consumption and body weight were measured weekly. Treatment of animals conformed to the Association for Research in Vision and Ophthalmology Resolution on Treatment of Animals in Research, as well as to specific institutional guidelines.
Measurement of NO
NO was determined by measuring the stable metabolites of NO (nitrate ϩ nitrite) using a fluorimetric assay kit (Cayman Chemical, Ann Arbor, MI) as reported previously by us (6) . This method has been shown to be specific and sensitive down to as little as 4 pmol in 0.12 ml according to manufacturer's instruction (26) . In each experiment, the three experimental groups (5 mM, 25 mM, and 25 mM ϩ therapy for cultured cells; or normal, diabetic, and diabetic ϩ therapy for in vivo experiments) were assayed simultaneously.
Western Blot Analysis
Retinas or cells were homogenized in buffer containing protease inhibitors (leupeptin 1 g/ml; aprotinin 1 g/ml), and 50 g of protein from each sample were loaded on 8% PAGE-SDS and transferred onto nitrocellulose membrane (Schleicher and Schuell, Keene, NH). Membranes were blocked overnight at 4°C with 5% nonfat dry milk and incubated with anti-iNOS polyclonal antibody (1:1,000 dilution; Transduction Laboratories, Lexington, KY) or COX-2 polyclonal antiserum (1:500 dilution; Cayman Chemical, Ann Arbor, MI) for 1 h at room temperature. Both blots were washed and incubated with anti-rabbit IgG antibody coupled to horseradish peroxidase (Bio-Rad) at a dilution of l:3,000 for another hour. After another extensive washing, protein bands detected by the antibodies were visualized by enhanced chemiluminescence (Amersham) and evaluated by densitometry (Molecular Dynamics). Prestained protein markers (Bio-Rad) were used for molecular mass determinations, and purified standards of iNOS (mouse macrophage; Transduction Laboratories, Lexington, KY) and COX-2 (ovine; Cayman Chemical) were used to confirm the identity of iNOS and COX-2 in the gels. To ensure equal loading among lanes, the membranes were stained with Ponceau S (Sigma, St. Louis, MO) and the intrinsic protein actin (mouse monoclonal anti-␤-actin antibody; Sigma) before and after, respectively, staining for iNOS and COX-2 (6). Protein concentration of tissue and/or cell lysates was measured by the Bradford procedure using the protein dye regent from Bio-Rad Laboratories and BSA as a standard.
Measurement of PGE 2
PGE2 in homogenized samples of retina (n ϭ 6 per group), Müller (6 observations in each group), and BREC cells (12 observations in each group) was measured by ELISA using a commercial kit (Cayman Chemical) following the instructions of the manufacturer. The retina tissue and/or cell culture medium (50 l) was assayed for immunodetectable PGE 2 using an enzyme immunoassay with rabbit antiserum specific for PGE2. All assays were done in duplicate and at two different dilutions of homogenate. The lower limit of sensitivity for this assay is 31 pg/ml, and all values reported were within the linear range of the assay. The amounts of PGE 2 in medium were corrected by the total amount of protein in the corresponding cell extracts. The protein content of each sample was determined by the Bradford procedure, and the PGE 2 content of each sample was calculated as picograms per milligram protein.
Cell Death
rMC-1 cells were incubated in 5 or 25 mM glucose, with or without L-NIL (30 M), L-NAME (1 mM), and NS-398 (50 M) and a combination of NS-398 (50 M) plus L-NIL(30 M). Media were changed every other day for up to 5 days. BREC cells were incubated in 5 or 25 mM glucose as well as inhibitors as described above for 5 days. Cell death was determined by light microscopy using a hemocytometer and a 0.4% trypan blue dye exclusion method. The number of cells that did not exclude the dye was expressed per 1,000 total cells. A minimum of 800 cells was counted per assay (8 dishes, Ͼ100 cells counted per dish), and the assay was replicated three times on different days.
Statistical Analysis
Data are expressed as means Ϯ SD. Statistical analysis was performed using the ANOVA followed by Fisher's test to correct for multiple comparisons. Similar conclusions were reached using nonparametric Kruskal Wallis test followed by Mann Whitney U-test.
RESULTS

Interrelationship of NOS and COX
In vitro studies using Müller cells. Incubation of rMC-1 cells in 25 mM glucose significantly increased cellular NO (as estimated by nitrite plus nitrate) compared with that measured at 5 mM glucose (P Ͻ 0.05), and iNOS expression also was increased (P Ͻ 0.001; Fig. 1, A-C) . A nonspecific inhibitor of NO production (L-NAME) as well as a selective inhibitor of iNOS (L-NIL, 30 M ) significantly inhibited NO accumulation (both P Ͻ 0.05) and iNOS expression, whereas an inhibitor of COX-2 (NS-398) had no effect on either (Fig. 1, A and B) . A different inhibitor of COX-2 (meloxicam) likewise had no effect on NO production or iNOS expression (not shown).
PGE 2 production and COX-2 expression also were measured in rMC-1 cells incubated at both glucose concentrations. Glucose at 25 mM increased PGE 2 released into the medium as well as expression of COX-2 compared with that at 5 mM glucose (P Ͻ 0.001; Fig. 1, D and E) . Inhibition of either NO production with L-NAME, or activities of iNOS or COX-2 with L-NIL or NS-398, respectively, significantly inhibited these glucose-induced increases of PGE 2 and COX-2 expression (all P Ͻ 0.05; Fig. 1, D and E) .
CELL VIABILITY. Incubation of rMC-1 cells in 25 mM glucose for 5 days significantly increased cell death compared with that in 5 mM glucose (P Ͻ 0.001; Fig. 2 ), and this increase was significantly inhibited by L-NAME, L-NIL, or NS-398. The combination of NS-398 plus L-NIL did not inhibit cell death significantly better than either agent alone, although it tended to do so.
In summary, incubation of rMC-1 cells in diabetic-like concentration of glucose increased NO production via iNOS, and this NO regulated the COX-2-mediated production of PGE 2 . Conversely, inhibition of COX-2 had no effect on NO production.
In vitro studies using retinal endothelial cells. In BREC, the concentration of nitrite plus nitrate in elevated 25 mM glucose increased above that in 5 mM glucose (P Ͻ 0.05), but L-NIL 
, aminoguanidine (AMG), and aspirin (Asp), but not by a cyclooxygenase (COX)-2 inhibitor (NS-398). * P Ͻ 0.001, 25 vs. 5 mM glucose, ** P Ͻ 0.05, 25 mM glucose ϩ therapy vs. 25 mM glucose (n ϭ 6 observations). B: elevated glucose increased expression of iNOS in rMC-1 cells, and this induction was inhibited by L-NAME, L-NIL, AMG, and ASP, but not by NS-398. * P Ͻ 0.001, 25 vs. 5 mM glucose, ** P Ͻ 0.05, 25 mM glucose ϩ therapy vs. 25 mM glucose. Data were reported relative to expression of actin on the same gel to ensure comparable loading of lanes (n ϭ 6 replicates). C: iNOS and COX-2 expression in rMC-1 cells or bovine retinal endothelial cells (BREC) incubated in 5 or 25 mM glucose, or in retinas from nondiabetic (ND) and diabetic (Diab) animals. Actin expression was comparable in each of the sample pairs. D: increase in PGE2 release from rMC-1 cells in 25 mM glucose was inhibited by NOS inhibitors, COX-2 inhibitor, and AMG and ASP. * P Ͻ 0.001, 25 vs. 5 mM glucose, ** P Ͻ 0.05, 25 mM glucose ϩ therapy vs. 25 mM glucose (n ϭ 6 observations). E: induction of COX-2 expression in rMC-1 cells by elevated glucose, and inhibition by therapies. * P Ͻ 0.001, 25 vs. 5 mM glucose, ** P Ͻ 0.05, 25 mM glucose ϩ therapy vs. 25 mM glucose. (n ϭ 6 replicates).
had no significant effect on its production. Inhibition of COX-2 with NS-398 had no significant effect on NO production (Fig.  3A) . The expression of iNOS did not change in elevated glucose (Fig. 1C) , and inhibitors of iNOS or COX-2 had no effect on its expression (not shown).
PGE 2 production by these vascular cells in 25 mM glucose likewise significantly increased above that in 5 mM glucose (P Ͻ 0.05). The COX-2 inhibitor (NS-398) significantly decreased the hyperglycemia-induced increase in production of PGE 2 . Inhibition of total NOS activity with L-NAME significantly inhibited PGE 2 production (P Ͻ 0.05), but L-NIL had no effect (Fig. 3B) , suggesting that NO increased production of PGE 2 also in this cell type but that iNOS was not responsible for the NO production. Elevated glucose concentration did not alter the expression of COX-2 in endothelial cells (Fig. 1C) , and neither L-NIL nor NS-398 affected the expression of COX-2 (data not shown).
Incubation of BREC cells in 25 mM glucose for 5 days significantly increased cell death compared with that in 5 mM glucose (P Ͻ 0.001), and this increase was partially, but significantly, inhibited by NS-398 or L-NAME (P Ͻ 0.05; Fig. 3C ).
In summary, production of NO by retinal endothelial cells incubated in 25 mM glucose increased compared with that in 5 mM glucose, but iNOS was not responsible for the increase. The NO generated in BREC incubated in 25 mM glucose does regulate COX-2 activity, and a product of COX-2 does contribute to endothelial death.
Effect of Aminoguanidine and Aspirin on iNOS, COX-2, and Their Products
In vitro studies. Aminoguanidine and aspirin significantly inhibited the glucose-induced upregulation of NO production and iNOS expression in rMC-1 cells(P Ͻ 0.05) (Fig. 1, A and  B) . The two therapies also significantly inhibited the increase in PGE 2 production and partially inhibited the induction of COX-2 in 25 mM glucose (Fig. 1, D and E) . In contrast to results in the glial cells, aminoguanidine had no significant effect on production of either NO or PGE 2 by BREC exposed to 25 mM glucose (Fig. 3, A and B) .
In vivo studies. Diabetic rats were hyperglycemic and failed to gain weight at a normal rate. Body weight at 8 -10 wk of study averaged 234 Ϯ 56, 290 Ϯ 28, 266 Ϯ 58, and 448 Ϯ 78 g for diabetic control, aminoguanidine-treated diabetic, aspirintreated diabetic, and nondiabetic rats, respectively. Serum glucose levels of the diabetic, aminoguanidine-treated, and aspirin-treated diabetic animals were greater than normal (301 Ϯ 45, 315 Ϯ 33, 313 Ϯ 98, and 57 Ϯ 7 mg/dl, respectively), and glycated hemoglobin levels likewise were greater than normal in the diabetic groups (9.0 Ϯ 1.4, 9.3 Ϯ 3.2, 11.5 Ϯ 1.5, and 3.3 Ϯ 0.4%, respectively).
The concentration of NO and PGE 2 in retinas of diabetic control rats was elevated more than threefold above that seen in retinal tissue from nondiabetic animals (P Ͻ 0.001), and treatment with aminoguanidine or aspirin significantly inhibited the diabetes-induced increases (both P Ͻ 0.05, respectively). The expression of iNOS and COX-2 proteins in retina of diabetic rats likewise was significantly increased compared with that in nondiabetic rats (P Ͻ 0.001), and administration of aminoguanidine or aspirin to the diabetic rats significantly inhibited the expression of the enzymes (both P Ͻ 0.05, respectively) ( Table 1 ). Fig. 3 . A: 25 mM glucose increased NO production in BREC cells, and this increase was not inhibited by inhibitor of iNOS, COX-2, or by AMG. * P Ͻ 0.05, 25 vs. 5 mM glucose (n ϭ 12 observations). B: increased production of PGE2 in BREC due to incubation in 25 mM glucose is inhibited by a general inhibitor of NOS (L-NAME) or an inhibitor of COX-2 (NS-398) but not by an inhibitor of iNOS (L-NIL) or AMG. * P Ͻ 0.05, 25 vs. 5 mM glucose, ** P Ͻ 0.05, 25 mM glucose ϩ therapy vs. 25 mM glucose (n ϭ 12 observations). C: NS-398 and L-NAME significantly inhibited the glucose-induced increase in death of BREC. * P Ͻ 0.001, 25 vs. 5 mM glucose, ** P Ͻ 0.05, 25 mM glucose ϩ therapy vs. 25 mM glucose (n ϭ 8 replicates). 
DISCUSSION
Diabetic retinopathy has been found in animals to be inhibited by therapies that, among other actions, inhibit production of NO (aminoguanidine) and prostaglandins (aspirin). Thus increased production of NO and prostaglandins is at least closely associated with the development of diabetic retinopathy, raising a question regarding their role in its pathogenesis. The inducible isoform of NOS (iNOS) has been found previously to be induced in the retina of diabetic animals (2, 6, 40), but the isoform of COX responsible for the increase in prostaglandin production has not been assessed. The present work demonstrates that both iNOS and COX-2 are induced in the retina in diabetes and that they or their products are related to hyperglycemia-induced death of retinal cells.
There is evidence that iNOS and COX-2 can regulate each other in some cell types. NO generated by iNOS increased PGE 2 release in astroglial cells, macrophages, osteoblasts, and air pouch, and this increase was at least partially attenuated by L-NAME, L-NIL, aminoguanidine, or NS-398 (17, 29, 35, 36, 38, 43) . Consistent with this, the hyperglycemia-induced increase in PGE 2 production was found to have been regulated by NO in rMC-1 cells in the present study. The molecular mechanism of this effect remains to be identified, but several possibilities are known. Peroxynitrite produced by the reaction of NO with superoxide can initiate lipid peroxidation, thereby releasing arachidonic acid from the cell membrane and potentially increasing COX activity (3, 23) . Additionally, NO could react with, and thereby remove, free radicals that can inactivate COX-2 (7, 37), or bind to the heme-Fe 2ϩ group of COX-2, thus directly activating the enzyme (36, 42) . Whatever the mechanisms of the interaction, the present study provides evidence that iNOS-derived NO modulates COX-2 enzymatic activity in retinal Müller cells exposed to elevated glucose. NO also activates COX-2 activity in retinal endothelial cells, but the NO apparently is not produced by iNOS in that cell type.
Conversely, products of the COX pathway have been reported to influence NO synthesis in J774.2 macrophages (24), to upregulate LPS-induced release of NO in rat Kupffer cells (10) , and to activate the nuclear transcription factor NF-kB and expression of NOS (34) . In this study, we found that selective inhibition of COX-2 had no significant effect on the glucoseinduced increase of NO in cultured retinal Müller or endothelial cells, thus providing no evidence that products of COX-2 play a major role in the regulation of NO production in retinal cells in diabetes.
Cell death plays an important role in the development of diabetic retinopathy (5) . Accelerated death of retinal capillary cells by an apoptotic-like process was found by us to be demonstrable in retinal endothelial cells and pericytes from diabetic humans and diabetic and experimentally galactosemic rats (28) before any other retinal histopathology is evident. Therapies that inhibit retinal capillary cell apoptosis in diabetes also inhibit the development of lesions characteristic of the early stages of the retinopathy (20) , suggesting that the capillary cell death plays a role in the ensuing development of acellular capillaries and retinal microvascular disease. Data presented herein suggest that NO and COX-2 play a role in hyperglycemia-induced death of retinal glial and endothelial cells in diabetes. A major source of the hyperglycemia-induced increase in NO in the Müller cells comes from iNOS, whereas other isoforms of NOS apparently account for the increase in NO produced in retinal endothelial cells. High concentrations of glucose also have been reported to induce cell death via NO production in differentiated PC12 cells (22) , and activation of NO and COX pathways increased cell death in cultured osteoarthritis synovial fibroblasts (16) .
Aminoguanidine (13, 14, 18) and high-dose aspirin (18) have been found to inhibit development of lesions of diabetic retinopathy in animals. We now demonstrate that these therapies also significantly inhibit the diabetes-induced increase in retinal NO and PGE 2 and in expression of iNOS and COX-2. Aminoguanidine is a relatively selective inhibitor of iNOS, inhibiting this inducible isoform better than either the endothelial or neural isoforms (IC 50 values for inhibition of murine iNOS and rat nNOS are 5.4 and 160 M, respectively) (25) . The evidence that aspirin, but not COX-2 inhibitors, blocked the hyperglycemia-induced increase in expression of iNOS in rMC-1 cells suggests that the effect of aspirin on iNOS expression was not mediated via prostaglandins. iNOS expression is regulated by NF-B, a transcription factor whose activity is known to be regulated by aspirin (21) . Neither aminoguanidine nor aspirin is a totally specific inhibitor of iNOS or COX-2 so other isoforms of NOS and COX might also be inhibited by these therapies (8, 41) .
We conclude that the increase in prostaglandin production detected in retinal cells incubated under diabetic-like conditions is secondary to increased production of NO. Whether PGE 2 itself directly kills cells is controversial (27, 32) , but our data suggest that COX-2 or its products play a role in the cell death. The source of the NO appears to differ among different retinal cell types, since iNOS contributes to NO production in Müller cells exposed to high glucose but not in endothelial cells. The available evidence suggests that the observed inhibition of early diabetic retinopathy by aminoguanidine or aspirin likely is due in part to inhibition of inflammatory mediators such as iNOS, COX-2, and production of nitric oxide and prostaglandins. Values are means Ϯ SD. Diabetes increases retinal content of nitric oxide (NO) or prostaglandin E2 (PGE2), and these are inhibited by either aminoguanidine (AMG) or aspirin (Asp). Likewise, retinal expression of inducible NO synthase (iNOS) and cyclooxygenase (COX)-2 is increased in diabetes and is inhibited by either AMG or Asp. *P Ͻ 0.001, diabetes vs. nondiabetic control.
†P Ͻ 0.05, diabetes ϩ therapy vs. diabetes control (n ϭ 6 observations).
